Hematological Malignancy: Clinical Trials

10 trials for Hematological Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 10
Phase 24Completed 4

Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
Nemtabrutinib - Hematological Malignancy
Phase 1CompletedMerck Sharp & Dohme LLC402023-08-282024-09-19
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Pelabresib - Advanced Malignancies, Solid Tumor
Phase 1CompletedConstellation Pharmaceuticals352021-07-202025-07-28
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Cord blood stem cells, Valproic Acid, Fludarabine - Hematological Malignancy, Acute Leukemia in Remission
Phase 1CompletedAlla Keyzner72019-02-212021-05-24
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
isavuconazonium sulfate - intravenous, isavuconazonium sulfate - oral - Hematological Malignancy
Phase 1CompletedAstellas Pharma Global Development, Inc.492017-10-022024-11-19
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
NK Cell infusion - Hematological Malignancy
Phase 1CompletedInstitut Paoli-Calmettes172013-04-012026-04-21
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®) - Hematological Malignancy
Phase 1 / Phase 2CompletedCorewell Health West282012-04-012023-06-02
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
AlloStim - Hematological Malignancy, Leukemia
Phase 1 / Phase 2CompletedMirror Biologics, Inc.62010-12-012020-01-22
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
Belinostat, Warfarin - Solid Tumor, Hematological Malignancy
Phase 1CompletedSpectrum Pharmaceuticals, Inc272010-12-012015-09-23
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Isatuximab SAR650984, Dexamethasone - Hematological Malignancy
Phase 1 / Phase 2CompletedSanofi3512010-05-112024-11-01
Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation
donor lymphocyte infusion - Hematological Malignancy
Phase 1 / Phase 2CompletedAssistance Publique - Hôpitaux de Paris112010-02-012013-01-14

Narrower conditions

Hematologic Neoplasms (10)  ·  Hodgkin Disease (2)  ·  Leukemia (2)  ·  Lymphoma (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Invasive Fungal Infections (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic Syndromes (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)

Broader conditions

Hematologic Diseases (10)  ·  Hemic and Lymphatic Diseases (10)  ·  Neoplasms (10)  ·  Neoplasms by Site (10)  ·  Bone Marrow Diseases (2)  ·  Disease Attributes (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms by Histologic Type (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Bacterial Infections and Mycoses (1)  ·  Blood Protein Disorders (1)

Interventions

Cyclophosphamide (2)  ·  ARQ531 (1)  ·  Bortezomib (1)  ·  Dexamethasone (1)  ·  Thiotepa (1)  ·  Valproic Acid (1)  ·  Warfarin (1)  ·  belinostat (1)  ·  fludarabine (1)  ·  isatuximab (1)  ·  isavuconazole (1)

Sponsors

Alla Keyzner (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Constellation Pharmaceuticals (1)  ·  Corewell Health West (1)  ·  Institut Paoli-Calmettes (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Mirror Biologics, Inc. (1)  ·  Sanofi (1)  ·  Spectrum Pharmaceuticals, Inc (1)

Countries

United States (7)  ·  France (3)  ·  Israel (2)  ·  Spain (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Chile (1)  ·  Finland (1)  ·  Georgia (1)  ·  Greece (1)  ·  Italy (1)  ·  Mexico (1)  ·  Peru (1)  ·  Russia (1)

Top investigators

A. Samer Al-Homsi, MD (1)  ·  Alla Keyzner, MD (1)  ·  Dr. Michael Har-Noy (1)  ·  Sunil Sharma, MD, FACP (1)

Results publications

PMID 32409691, PMID 32718876, PMID 33080623, PMID 34031051, PMID 34071607